Statement of Principles concerning Kaposi sarcoma (Balance of Probabilities) (No. 2 of 2020)

The instrument’s central legal concept is causation on the “balance of probabilities” within the statutory framework under which Statements of Principles operate. The Repatriation Medical Authority states it is of the view, based on sound medical‑scientific evidence, that it is more probable than not that Kaposi sarcoma and death from Kaposi sarcoma can be related to relevant service by veterans or members of the Forces under the VEA, or members under the MRCA (s 8). That evidentiary posture underpins the rest of the instrument: it identifies specific medical or treatment-related factors that must exist before a connection with relevant service can be accepted for the purposes of claims (s 9).

Key definitional concepts are given statutory effect in s 7 and Schedule 1:

• Kaposi sarcoma is defined as “a multicentric vascular neoplasm arising from endothelial cells and characterised by the proliferation of spindle cells, formation of new blood vessels and inflammation,” and the definition explicitly excludes soft tissue sarcoma (s 7(2)). The instrument notes typical clinical manifestations and ties Kaposi sarcoma to ICD‑10‑AM code C46 but directs that the statutory definition in s 7(2) controls when applying this Statement of Principles (s 7(3)-(4)).

• Death from Kaposi sarcoma is taken to include death from a terminal event or condition that was contributed to by the person’s Kaposi sarcoma; “terminal event” is defined in Schedule 1 to include proximate or ultimate causes of death such as pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function (s 7(5); Schedule 1).

Causation is operationalised by a gatekeeping list of factors in s 9. At least one listed factor must exist before it can be said, on the balance of probabilities, that Kaposi sarcoma or death from Kaposi sarcoma is connected with the circumstances of a person’s relevant service (s 9). The factors are time-sensitive or contingent:

• Infection with human herpesvirus type 8 (HHV‑8) or with human immunodeficiency virus (HIV) must have occurred before the clinical onset of Kaposi sarcoma (s 9(1)-(2)).

• Prior diagnoses of non-Hodgkin lymphoma or chronic lymphocytic leukaemia/small lymphocytic lymphoma before clinical onset are qualifying factors (s 9(3)).

• Prior solid organ, stem cell or bone marrow transplantation before clinical onset is a qualifying factor (s 9(4)).

• Treatment with an “immunosuppressive drug” for a continuous period of at least three months before clinical onset, with provision that if exposure has ceased the clinical onset must have occurred within ten years of cessation (s 9(5); Schedule 1 defines “immunosuppressive drug” and gives examples).

• Treatment with an ACE inhibitor for at least three months before clinical onset, again with the ten-year post-cessation window if exposure has ceased (s 9(6)).

• An inability to obtain appropriate clinical management is recognised as a qualifying factor (s 9(7)), but s 10(2) limits the application of that factor: it applies only to material contribution to, or aggravation of, Kaposi sarcoma where the person’s Kaposi sarcoma was suffered or contracted before or during (but did not arise out of) the person’s relevant service.

Section 10 requires that any factor relied on under s 9 must be related to the person’s relevant service (s 10(1)). Finally, s 11 addresses cross-references to other Statements of Principles where a factor in s 9 refers to another injury or disease already covered by a separate Statement: in such cases, the terms of that other Statement apply.

Collectively, these concepts convert medical findings and treatment histories (infection status, history of malignancy or transplantation, drug exposure windows, treatment access) into legal thresholds for establishing service-relationship in VEA/MRCA claims.

The instrument affects several identifiable groups through its application to claims under the VEA and the MRCA. The text itself limits application to “a claim to which section 120B of the VEA or section 339 of the MRCA applies” (s 5). Those statutory provisions are the procedural hooks; the Statement of Principles operates within those claims processes.

Primary affected persons and actors, as derivable from the instrument text, are:

• Claimants: veterans or members of the Forces (or their dependants for death claims) who lodge claims under the VEA or MRCA that assert Kaposi sarcoma or death from Kaposi sarcoma is connected to relevant service. The instrument prescribes what medical facts must be shown to establish that connection (s 9).

• Medical professionals: clinicians providing diagnostic evidence, histopathology, serology, transplant histories, medication histories and expert opinions will be required to supply information that maps to the factors in s 9. The instrument’s timing requirements (for example, infection “before the clinical onset”, continuous drug treatment “for a continuous period of at least three months”, and the ten-year post-cessation window) create documentary and evidential tasks for treating clinicians and forensic/expert witnesses (s 9(1), s 9(5)-(6)).

• Decision-makers and administrators operating under the VEA and MRCA frameworks: the Repatriation Medical Authority made the instrument (s 3), and the instrument is intended for use by the statutory decision-makers assessing entitlement under the relevant claims provisions (s 5). That includes officers and medical panels who must apply the listed factors when determining causation in claims.

• Persons with medical histories referenced in the factors: people who have documented infection with HHV‑8 or HIV, prior non-Hodgkin lymphoma or chronic lymphocytic leukaemia/small lymphocytic lymphoma, recipients of solid organ or stem cell/bone marrow transplants, patients treated with immunosuppressive drugs (as defined in Schedule 1) or ACE inhibitors, and those who can show inability to obtain appropriate clinical management. These are the survivor groups whose pre-existing medical states or treatments are mapped by the instrument into qualifying factors (s 9; Schedule 1).

• Entities responsible for medical records, pharmacy records and prescription histories: demonstrating “being treated” for periods of time and cessation dates will typically involve records held by hospitals, pharmacies and treating practitioners. The instrument’s reliance on treatment durations and cessation windows (s 9(5)-(6)) makes those records material.

The instrument also affects the legal relationships between Statements of Principles. If a factor in s 9 refers to an injury or disease covered by another Statement made under s 196B(3) of the VEA, the factors in that other Statement apply as in force from time to time (s 11). That means claimants and clinicians must be attentive to other Statements when a qualifying factor points to a separate disease (for example, a factor referring to non-Hodgkin lymphoma where there is a separate Statement on that disease).

The instrument does not itself create a duty to pay benefits, impose criminal penalties, or change entitlement mechanics beyond providing the causation criteria. Its operation is procedural and evidentiary within VEA/MRCA claim decision-making (see s 5; s 8).

This instrument is not framed as a statute imposing novel criminal or administrative duties; rather it supplies legal and evidential rules that must be applied to determine whether Kaposi sarcoma or death from Kaposi sarcoma is connected to relevant service for the purposes of VEA and MRCA claims. The core duties and rights that arise from the instrument are therefore procedural and evidentiary.

Rights established or clarified by the instrument

• Right to rely on a prescribed causal framework: a claimant to whom s 120B (VEA) or s 339 (MRCA) applies can have the causal relationship between Kaposi sarcoma (or death from it) and their relevant service considered using the Repatriation Medical Authority’s specified factors (s 5; s 9). In practice, the instrument gives claimants a clear list of medical circumstances that, if established, satisfy the causation threshold “on the balance of probabilities” as articulated by the RMA (s 8).

• Right to have cross-referenced factors applied: where a factor in s 9 refers to an injury or disease covered by another Statement of Principles, the claimant benefits from the application of that other Statement’s factors as they stand from time to time (s 11). This creates a right to have established inter-Statement links respected by decision-makers.

Duties or obligations implicated by the instrument

• Duty to demonstrate qualifying factors: the claimant bears the evidential task of proving that at least one of the factors in s 9 existed and was related to their relevant service (s 9; s 10(1)). The text makes timing and continuity requirements explicit for some factors (for example, continuous treatment for at least three months; onset within ten years of cessation) and so the duty includes producing medical records that establish those elements (s 9(5)-(6)).

• Duty to show relationship to relevant service: s 10(1) makes clear that any factor must be related to the relevant service rendered by the person. This requirement creates an evidentiary burden to link the qualifying medical factor to the period or circumstances of relevant service.

• Duty as to the application of factors referring to other Statements: where a factor refers to a condition covered by another Statement, the application is governed by that other Statement as in force (s 11). This imposes a duty to engage with the relevant current Statements when such cross-references arise.

Procedural features affecting duties/rights

• Balance of probabilities standard: the RMA states the basis for its determination in terms of “more probable than not” (s 8); all fact-finding under the instrument is to be conducted to that civil standard. That standard governs whether the claimant’s evidence meets the instrument’s requirements.

• Technical definitions and evidential thresholds: the Schedule defines “immunosuppressive drug” and provides examples, excludes inhaled or topical corticosteroids from that category, and defines “relevant service” and “terminal event” (Schedule 1). Those definitions affect what evidence is required to satisfy the factors and create duties on clinicians and record-keepers to provide relevant, precise information.

What the instrument does not do (limits)

• It does not itself create entitlement or specify benefits payable. The instrument is a Statement of Principles to be applied within the VEA/MRCA claims procedures (s 5). Any actual entitlement and payment mechanics remain determined by the VEA or MRCA provisions and the decisions taken under them.

• It does not set investigative powers, offence provisions, or administrative sanctions. The instrument sets evidential rules; it does not create offences or enforcement mechanisms within its text.

In sum, the instrument creates a structured evidentiary regime for establishing causation in Kaposi sarcoma claims. The principal duty is on the claimant to establish, with appropriate documentary and clinical evidence, that at least one qualifying factor in s 9 applied and was related to their relevant service, with the RMA’s balance-of-probabilities standard as the legal threshold (s 8; s 9; s 10).

The Statement of Principles instrument contains no penal provisions, administrative penalties, or enforcement mechanisms within its text. It is an instrument made under s 196B(3) of the VEA that sets causation criteria for use in claims under the VEA and MRCA (s 3; s 5). The instrument itself does not prescribe or alter enforcement authorities, investigation powers, civil penalties or criminal liability.

How the instrument operates practically as an enforcement-adjacent tool

• Evidentiary gatekeeping function: the instrument functions as a regulatory evidentiary tool within the VEA and MRCA claims framework. By identifying the factors which must exist before a connection between Kaposi sarcoma (or death from it) and relevant service can be established, decision-makers use the instrument to accept or reject a claimant’s assertion of service connection. That is the primary mechanism by which the instrument affects outcomes, but these are administrative decision-making consequences rather than sanctions contained in the instrument itself (s 9; s 10).

• Repeal and currency: s 4 repeals the prior Statement of Principles No. 10 of 2011 (F2010L03267). Repeal operates as an internal compliance change for decision-makers and claimants, who must now apply the current Statement in place of the repealed instrument.

What is absent

• The instrument does not create investigatory or enforcement powers for the Repatriation Medical Authority or other agencies. It does not require any specific procedural steps for verifying medical records or compel disclosure. It provides standards to be applied in the statutory claims process but leaves implementation (collection and assessment of evidence, and the decision to grant a benefit) to the bodies and procedures established in the VEA and MRCA (s 5).

• No penalties are attached to false statements or fraudulent claims within this instrument. The broader VEA or MRCA frameworks may include sanctions or offences elsewhere, but those are not recited or created in this Statement of Principles.

Consequences for administrative decisions

• Use in decision-making: by prescribing which medical states and treatment histories qualify, the instrument affects whether administrative decision-makers accept causation and, by extension, whether a claim proceeds to entitlement. That is the instrument’s enforcement-adjacent effect.

• Potential for administrative review or legal challenge: while the instrument itself does not specify appeal or review routes, decisions that apply it within the VEA/MRCA regime will be subject to the statutory review, reconsideration or merits review mechanisms provided by those Acts. The instrument does not itself change those avenues.

In sum, enforcement in practical terms is the instrument’s use by decision-makers within the VEA/MRCA processes to accept or reject causation in claims; the instrument contains no independent penal or enforcement measures (see s 3-5; s 9; s 11; Schedule 1).

This Statement of Principles is explicitly made under subsection 196B(3) of the VEA and is designed to be applied within the decision-making architecture established by the VEA and the MRCA. Several direct interactions with other legal instruments and standards are apparent in the text.

Primary statutory interaction

• VEA and MRCA claims framework: the instrument applies to claims to which s 120B of the VEA or s 339 of the MRCA applies (s 5). That means the instrument’s factors feed directly into the causation analysis required by those claim provisions. The instrument does not replace the VEA or MRCA; it supplies medical causation guidance to be used in adjudication under those Acts.

Interaction with other Statements of Principles

• Where a factor in s 9 refers to an injury or disease that is the subject of another Statement of Principles made under s 196B(3) of the VEA, s 11 provides that the factors in that other Statement apply “in accordance with the terms of that Statement of Principles as in force from time to time”. This creates a dynamic legal interaction: adjudicators must consult other Statements and apply their current terms when cross-references exist (s 11). The effect is to fold the content of other Statements into the causal analysis where those conditions are implicated.

Interaction with medical classification standards

• ICD‑10‑AM cross-reference: s 7(3)-(4) notes that while Kaposi sarcoma attracts ICD‑10‑AM code C46, the statutory meaning in s 7(2) controls in applying the Statement. The instrument specifically references the ICD‑10‑AM Tenth Edition, effective date 1 July 2017, and identifies its copyright owner and ISBN (s 7(4)). This signals that clinical coding may be relied upon, but the statutory textual definition is determinative.

Interaction with clinical and pharmaceutical practice

• Definitions affecting clinical categories: Schedule 1 defines “immunosuppressive drug” and lists examples such as chemotherapeutic agents, corticosteroids (excluding inhaled or topical), drugs used to prevent transplant rejection, and tumour necrosis factor‑α inhibitors. That definition interacts with pharmaceutical practice in that the instrument’s inclusion or exclusion of particular therapeutic classes will affect which medication histories qualify under s 9(5). For example, inhaled or topical corticosteroids are excluded from the term “immunosuppressive drug” in Schedule 1.

Temporal interactions with statutory causation standards

• Balance-of-probabilities standard: the RMA sets out its evidentiary threshold as “more probable than not” (s 8). That standard aligns with civil evidentiary norms and interacts with the VEA/MRCA legal framework by informing how adjudicators assess evidence of infection, treatment, transplantation, or inability to obtain management.

Limitations on statutory reach

• The Statement does not alter substantive entitlements under the VEA or MRCA; it operates as a rule of application within those Acts. It does not, for example, create new criminal offences or new entitlements; it clarifies causal links for administrative decision-making (s 5; s 8).

Cross-reliance and amendment dynamics

• Because s 11 incorporates other Statements “as in force from time to time”, there is an ongoing interdependence between Statements. Amendments to other Statements (or to the current one) will change how factors that refer to other diseases are applied. Repeal of a prior Statement is exemplified by s 4, which repeals the 2011 Statement, demonstrating that the instrument’s legal landscape is subject to discrete revisions over time.

In summary, the Statement interacts with the VEA/MRCA statutory claim processes, other Statements of Principles, clinical classification tools such as ICD‑10‑AM, and clinical/pharmaceutical definitions provided in the Schedule. It is a procedural-evidentiary instrument that must be read and applied in the context of the wider statutory and regulatory claim environment (s 3-5; s 7; s 11; Schedule 1).

The instrument’s internal text records limited amendment history and change events. The text itself provides the following chronological and amendment-related data:

• Date of the instrument: the Statement of Principles concerning Kaposi sarcoma (Balance of Probabilities) (No. 2 of 2020) is dated 20 December 2019 (s 1 preamble). The instrument states its commencement date as 27 January 2020 (s 2).

• Repeal of predecessor: s 4 expressly repeals the Statement of Principles concerning Kaposi's sarcoma No. 10 of 2011 (Federal Register of Legislation No. F2010L03267), which was made under subsection 196B(3) of the VEA. The repeal instructs decision-makers and claimants to apply the current instrument rather than the 2011 Statement.

• “As in force from time to time” provision: s 11 provides that where a factor in this Statement refers to an injury or disease covered by another Statement of Principles made under s 196B(3) of the VEA, the factors in that other Statement apply “in accordance with the terms of that Statement of Principles as in force from time to time”. This language anticipates that other Statements may be amended, replaced or repealed in the future; it thereby creates a statutory mechanism for subsequent amendments in related instruments to affect the application of this Statement without the need to amend this text each time.

Matters not recorded in the instrument

• The instrument contains no internal amendment log beyond the explicit repeal of the 2011 Statement. It does not document prior drafts, consultation steps, or edition changes beyond the ICD‑10‑AM edition referenced at s 7(4).

• There is no provision in the instrument setting out a specific sunset clause or scheduled review date. The “as in force from time to time” cross-reference in s 11 indicates reliance on external Statements’ currency rather than an internal revision timetable.

Practical implications for users

• After 27 January 2020 the 2011 Statement ceased to apply; all claims falling within the remit of s 120B VEA or s 339 MRCA should be assessed against the factors in the 2020 Statement (s 2; s 4; s 5).

• Adjudicators and practitioners must monitor changes to other Statements of Principles because s 11 incorporates their terms dynamically. If an associated Statement is amended, the applicable factors for cross-referenced conditions may change without amendment to this document.

• The instrument anchors itself to a specific edition of ICD‑10‑AM (Tenth Edition, effective 1 July 2017) when referencing the code for Kaposi sarcoma, but it clarifies that the statutory definition in s 7(2) is the operative meaning for this Statement (s 7(3)-(4)). If a future edition or replacement classification is adopted administratively, the instrument does not itself update that reference; amendment would require a further instrument or a different interpretive approach by decision-makers.

In sum, the amendment history recorded within this instrument is limited to its date, commencement, and the repeal of the 2011 Statement. The instrument is structured to be responsive to changes in other Statements via s 11, but contains no internal schedule for revision (s 1-5; s 11; s 7(4)).

The document supplied contains no litigation history. The instrument itself does not list any court decisions, judicial interpretations, or administrative appeals that have tested its provisions. It contains no references to case law, no discussion of prior adjudications, and no summary of legal challenges to either the current instrument or the repealed 2011 Statement (compare s 4).

Consequences of the absence of litigation history in the text

• No source-provided precedents: because the Statement does not cite or summarise judicial decisions, practitioners must rely on the instrument’s text and the VEA/MRCA statutory framework rather than any declared judicial construction contained in the instrument.

• Potential areas for dispute not addressed in the instrument: several provisions contain fact-sensitive or interpretive elements where litigation could arise (for example, the meaning of “before the clinical onset”, the evidentiary thresholds for establishing infection timing, the scope of “inability to obtain appropriate clinical management”, or whether particular medications qualify as “immunosuppressive drugs” within Schedule 1 examples). The instrument does not provide judicial gloss; it leaves those interpretive questions to decision-makers or courts outside the instrument text.

Practical effect for litigators and reviewers

• When litigating decisions that apply this Statement, practitioners should not expect the instrument itself to cite judicially-developed standards. Instead, challenges to administrative decisions that apply these factors will be based on the statutory text and the way decision-makers have applied relevant evidence in individual cases, using general principles of administrative law, statutory interpretation and the VEA/MRCA frameworks.

• Because s 11 integrates other Statements “as in force from time to time”, litigation that addresses cross-referenced Statements could have cascading effects; however, the instrument does not record any such litigation outcomes.

• Any legal challenge to a decision applying this Statement will likely centre on the sufficiency and interpretation of the medical evidence relative to the s 9 factors and on the statutory requirement that the factor be related to the person’s relevant service (s 9; s 10).

In summary, the instrument does not include a litigation history. Practitioners must therefore approach application and potential challenges on the basis of the statutory text, clinical evidence and the general bodies of administrative and statutory law that govern VEA/MRCA decisions, none of which are summarised within the Statement itself.

The instrument contains multiple textual features and technical thresholds that are likely to catch practitioners and claimants unawares if relied upon without careful scrutiny. Below are concrete “gotchas” grounded in the instrument text and their practical implications.

1. Statutory definition controls over ICD code

• The instrument notes that Kaposi sarcoma attracts ICD‑10‑AM code C46 but makes clear that the meaning of Kaposi sarcoma for the instrument is the definition in s 7(2) (s 7(3)). That means mere assignment of ICD code C46 in a record does not displace the statutory elements in s 7(2). Practitioners must ensure the clinical description matches the statutory definition.

2. Timing requirements for infections and treatments

• Several qualifying factors require that the condition or exposure existed “before the clinical onset” of Kaposi sarcoma (s 9(1)-(4)). Proving that infection or a prior malignancy predates clinical onset requires precise dates and records; retrospective or indeterminate timing evidence may fail to meet the “before” test.

• For drug-based factors (immunosuppressive drugs and ACE inhibitors), the instrument requires “being treated … for a continuous period of at least three months before the clinical onset” (s 9(5)(a); s 9(6)(a)). Continuity and duration must be established. Gaps in prescriptions or treatment records may break the required continuity.

• Where drug exposure has ceased, the instrument permits connection only if clinical onset occurred within ten years of cessation (s 9(5)(b); s 9(6)(b)). This is a firm temporal window that can exclude long-lag presentations.

3. Narrow definition of “immunosuppressive drug”

• Schedule 1 defines “immunosuppressive drug” and explicitly excludes inhaled or topical corticosteroids (Schedule 1). A claimant treated only with inhaled or topical corticosteroids cannot rely on s 9(5) by virtue of that exclusion. The Schedule lists examples, but the definition is also framed in terms of “substantial suppression of immune responses”, which is a clinical threshold requiring evidence.

4. The ability-to-obtain-treatment factor is conditional and limited

• s 9(7) recognises “inability to obtain appropriate clinical management” as a qualifying factor, but s 10(2) limits its application: it applies only to material contribution to, or aggravation of, Kaposi sarcoma where the Kaposi sarcoma was suffered or contracted before or during (but did not arise out of) the person’s relevant service. So the inability-to-treat factor cannot be used to establish that Kaposi sarcoma arose out of service; it is limited to material contribution or aggravation in specific timing circumstances.

5. Relationship to relevant service required in all cases

• s 10(1) requires that any factor in s 9 be “related to the relevant service rendered by the person.” Establishing that nexus is an independent evidentiary task; satisfying the listed medical factor alone is insufficient if it cannot be linked to the period, exposure or conditions of relevant service.

6. Cross-Statement dependencies

• If a factor in s 9 points to an injury or disease covered by another Statement of Principles, the application depends on the other Statement “as in force from time to time” (s 11). Practitioners must check the current version of the other Statement; relying on an earlier version could be detrimental.

7. Death-related scope , “death from” includes contribution to terminal events

• Death from Kaposi sarcoma “includes death from a terminal event or condition that was contributed to by the person’s Kaposi sarcoma” (s 7(5)). The Schedule’s definition of “terminal event” lists several proximate causes (pneumonia, respiratory failure, cardiac arrest, etc.). Establishing contribution to such terminal events requires medical evidence linking the Kaposi sarcoma to the terminal event, not merely the presence of the terminal event.

8. Repeal creates transition considerations

• The 2011 Statement is repealed (s 4). If a claim straddles the repeal/commencement dates, practitioners should confirm which Statement governs the claim’s decision-making date. The instrument itself does not provide transitional rules; administrative practice will determine application.

9. “Being treated with” language requires objective medical documentation

• The factors use the phrase “being treated with” (s 9(5), s 9(6)). Subjective self-report without corroborating prescription, dispensing, or clinician records will be weak evidence. The requirement for a continuous period and the ten-year cessation window amplify the need for documentary proof.

10. The instrument is evidentiary, not determinative of entitlement

• Meeting a factor in s 9 establishes that, on the balance of probabilities, Kaposi sarcoma can be related to relevant service; the instrument does not itself create a benefit or guarantee entitlement under the VEA or MRCA. Claimants and advisors must remember that the Statement forms part of the evidentiary matrix applied in statutory decision-making (s 5; s 8).

Each of these items is grounded in the text of the instrument (s 7; s 9; s 10; s 11; Schedule 1). Practitioners handling claims should map clinical evidence precisely to these textual tests and be alert to the temporal and definitional traps that can cause otherwise plausible cases to fail.

Compliance in the context of this Statement of Principles means preparing and presenting evidence in VEA or MRCA claims so that decision-makers can determine, on the balance of probabilities, whether one or more of the s 9 factors existed and were related to the person’s relevant service (s 5; s 8; s 9; s 10). The following is a practical checklist and evidential roadmap anchored to the instrument text.

1. Identify the applicable statutory claim hook

• Confirm the claim falls within the scope of s 120B of the VEA or s 339 of the MRCA (s 5). If it does not, this Statement of Principles does not apply.

2. Establish the diagnosis consistent with the statutory definition

• Ensure medical records document Kaposi sarcoma in terms that align with the statutory definition in s 7(2): multicentric vascular neoplasm arising from endothelial cells with spindle cell proliferation, neovascularisation and inflammation. Histopathology, oncologist reports and imaging are primary evidence.

• Do not rely solely on ICD‑10‑AM code C46 as determinative. While the code is referenced (s 7(3)-(4)), the statutory clinical definition in s 7(2) governs.

3. Prove timing: “before the clinical onset” and continuous exposure windows

• For s 9(1)-(4) factors (HHV‑8, HIV, prior non‑Hodgkin lymphoma or chronic lymphocytic leukaemia, transplants): produce dated medical records, serology reports, biopsy dates, admission summaries, oncological records and pathology reports that demonstrate the condition or event occurred before the clinical onset of Kaposi sarcoma. The instrument requires the antecedent to pre-date clinical onset (s 9(1)-(4)).

• For drug exposures (s 9(5), s 9(6)): assemble prescription records, pharmacy dispensing histories, hospital medication charts, treatment summaries, or specialist letters that document continuous treatment for at least three months prior to clinical onset. If treatment ceased, supply documentation of cessation dates and evidence to show the clinical onset occurred within ten years of cessation (s 9(5)(b); s 9(6)(b)).

4. Demonstrate treatment class fits Schedule 1 definitions

• Where relying on s 9(5), ensure the drug is an “immunosuppressive drug” as defined in Schedule 1. Provide the drug name, dosage, route of administration and clinical purpose. Be mindful that inhaled or topical corticosteroids are excluded from the Schedule 1 examples; if treatment was only via those routes, s 9(5) will not be satisfied.

• Where relying on s 9(6), document ACE inhibitor use in the same way, with continuity and cessation information.

5. For transplant-related factors, document the transplant and immunosuppressive regimen

• For s 9(4) (solid organ, stem cell or bone marrow transplantation), provide the operative or transplant discharge summaries, transplant registry entries, immunosuppressive medication regimens, and follow-up clinic notes. Show that the transplant preceded clinical onset.

6. For infection-related factors, secure laboratory and specialist evidence

• For s 9(1) and s 9(2), provide serological or molecular test results (with dates), specialist infectious disease notes or hospital records confirming HHV‑8 or HIV infection and demonstrating the positive result pre-dated clinical onset.

7. For “inability to obtain appropriate clinical management” (s 9(7)):

• Because s 10(2) restricts this factor to material contribution to or aggravation of Kaposi sarcoma where the disease was suffered or contracted before or during (but did not arise out of) relevant service, provide contemporaneous records showing attempts to access appropriate management, correspondence or referrals denied or delayed due to service-related circumstances, and clinical notes linking lack of management to disease progression. Document dates, providers contacted, and any official or administrative barriers encountered.

8. Establish nexus to relevant service

• For all factors, document how the qualifying factor is related to the claimant’s relevant service (s 10(1)). This may include service medical records, deployment histories, exposure records, administrative notes, or contemporaneous clinical entries linking a disease onset or treatment interruption to service circumstances.

9. Check cross-referenced Statements of Principles

• If a factor refers to a condition that is the subject of another Statement of Principles (for example, non‑Hodgkin lymphoma), obtain and apply the current version of that Statement, because s 11 requires that the factors in that other Statement apply “as in force from time to time”. Ensure the other Statement’s factors are satisfied if the factor is dependent on them.

10. Prepare structured expert opinions

• Because the instrument sets medical facts as determinative of causation, obtain clear medico-legal or specialist expert reports that map the claimant’s medical history to the s 9 factors and address timing, continuity and relation to relevant service using the balance-of-probabilities standard (s 8). Experts should explicitly state whether they consider a listed factor existed before clinical onset and whether it was related to relevant service.

11. Provide clear chronology and index evidence

• Given the time-sensitive thresholds (pre-onset requirements, three-month continuous treatment, ten-year cessation window), supply a clear chronology of diagnoses, treatments, cessations and clinical onset dates. Index the supporting documents (lab reports, prescriptions, hospital notes) to the chronology for assessor convenience.

12. Address possibility of exclusionary hurdles

• Be aware of exclusions in definitions (for example, inhaled/topical corticosteroids) and ensure that claimed treatments fall within the Schedule 1 definition of “immunosuppressive drug” or the ACE inhibitor class. If not, prepare alternative evidential pathways, such as establishing HHV‑8 or HIV infection before onset.

13. Administrative follow-through

• Ensure any cross-references to other Statements are checked and that the current versions of those Statements are applied. If the claim straddles the instrument’s repeal/commencement date, confirm which Statement applied at the relevant decision date.

In short, compliance requires precise, dated clinical documentation that maps to the instrument’s enumerated factors and timing requirements, explicit linkage of qualifying factors to relevant service, and, where necessary, expert interpretation that applies the balance-of-probabilities standard to those facts (s 7; s 9; s 10; s 11; Schedule 1).